Sanofi India’s Analyst Call Highlights: ICICI Securities  
Blister packs containing Priadel tablets, produced by Sanofi, sit on a pharmacy counter. (Photographer: Chris Ratcliffe/Bloomberg)

Sanofi India’s Analyst Call Highlights: ICICI Securities  

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Securities Report

Sanofi India Ltd.’s is poised to grow owing to its high chronic exposure in the domestic market supported by strong balance sheet with deep cash reserves, and strong brand equity built over the years.

We cover the highlights from its virtual investor meet below -

The company believes that its performance has been resilient during the past few months as it was not materially affected by any breakdown of logistics or shortage of raw materials as well as higher exposure to chronic therapies (diabetic and cardiac).

Lockdown caused a postponement of elective surgeries as well as large part of ICU beds were utilized for Covid-19 patients.

This negatively affected drugs like Targocid but on the other hand inclusion of Clexane in the Covid-19 drug regime saw a sharp demand in it.

Click on the attachment to read the full report:

ICICI Securities Sanofi Company Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.